01 JULY 2017
`
` S.J. Mathew, M.D.
`
`1
`
`SANJAY J. MATHEW, M.D.
`
`Baylor College of Medicine
`Menninger Department of Psychiatry &
`Behavioral Sciences
`One Baylor Plaza MS: BCM350
`Houston, Texas 77030
`Phone: (713) 798-5877
`sjmathew@bcm.edu
`
`Veterans Affair Medical Center
`Michael E. Debakey VA Medical Center
`MHCL, Room 6B-312
`2002 Holcombe Blvd
`Houston, Texas 77030
`Phone: (713) 791-1414
`
`I.
`
`GENERAL BIOGRAPHICAL INFORMATION
`
`A. Personal
`1. Name: Sanjay Johan Mathew, M.D.
`2. Citizenship: U.S.
`B. Education
`1. Undergraduate Education: Dartmouth College/Hanover, NH, A.B. Biology, 1991
`2. Medical Education: Baylor College of Medicine/Houston, TX, M.D., 1997
`3. Postgraduate Training
`A. Columbia-Presbyterian Hospital/New York, NY, Internship, 1997-1998
`B. New York State Psychiatric Institute (NYSPI)/New York Presbyterian, Residency, 1998-2001
`C. Columbia University/NIMH T32 Research Fellowship in Mood/Anxiety Disorders (advisors:
`Harold Sackeim, Ph.D., Jack Gorman, M.D.), 2001-2004
`C. Academic Appointments
`1. Faculty position(s) at Baylor College of Medicine:
`A. Professor of Psychiatry (with Tenure), Menninger Dept of Psychiatry, 2016-present
`B. Staff Physician, Michael E. Debakey VA Medical Center, 2010-present
`C. Director, Mood & Anxiety Disorders Program, 2010-present
`D. Johnson Family Chair for Research in Psychiatry, 2014-present
`E. Brown Foundation Chair for Psychopharmacology of Mood Disorders, 2012-2014
`F. Associate Professor, Menninger Dept of Psychiatry, 2010-2016
`2. Previous faculty position(s) at other institutions:
`A.
`Investigator, The Methodist Hospital Research Institute, 2010-2014
`B. Associate Professor of Psychiatry, Mount Sinai School of Medicine (MSSM), 2009
`C. Director, Mood & Anxiety Disorders Program, MSSM, 2008-2009
`D. Associate Professor, Graduate School of Biological Sciences, MSSM, 2009
`E. Assistant Professor of Psychiatry, MSSM, 2004-2008
`F. Assistant Professor of Clinical Psychiatry, Columbia University College of Physicians &
`Surgeons, 7/1/04-7/31/04
`G. Attending Physician, Brain Behavior Clinic and ECT service, NYSPI, 7/1/02-7/31/04
`H.
`Instructor/Assistant in Psychiatry, Columbia University, 7/1/01-6/30/04
`
`Argentum EX1024
`
`Page 1
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`
`2
`
`3. Faculty appointment(s) at other institutions while at BCM:
`A. Professorial lecturer, Mount Sinai School of Medicine, 2010-present
`D. Other advanced training/experience: (with locations, dates and sources of support)
`1. Formal Sabbatical leave: N/A
`2. Other specialized training following academic appointment:
`A. Medical License #211078, New York, 1998-
`B. Diplomate, American Board of Psychiatry and Neurology, 2002 (recertification in 2012)
`C. Medical License #N5849, Texas, 2010- (registered through 8/31/17)
`D. Buprenorphine Prescribing Course, 2015 (DATA Waiver #56844)
`
`E. Other information
`1. Honors or Awards
`A. Hilde Bruch Medical Student Excellence Award, Baylor College of Medicine, 1997
`B. Ethics Track Certificate, Baylor College of Medicine, 1997
`C. Columbia University House Staff Research Award, 1998
`D. American Psychiatric Association/Lilly Resident Research Award, 2001
`E. Anxiety Disorders Association of America Trainee Travel Award, 2001
`F. Arnold P. Gold Foundation Outstanding Resident Teaching Award, 2001
`G. Distinguished Laughlin Fellow, Columbia Univ College of Physicians & Surgeons, 2001
`H. Columbia University Alumni Association Outstanding Teaching Award, 2001
`I. American Psychiatric Association Colloquium for Young Investigators, 2001
`J. American College of Neuropsychopharmacology Memorial Travel Award, 2003
`K. NARSAD Young Investigator Award, 2001 and 2006
`L. American Foundation for Suicide Prevention Pfizer Travel Award, 2007
`M. Dr. Harold and Golden Lamport Research Award, Mount Sinai School of Medicine, 2007
`N. Excellence in Psychiatry Education Award, Mount Sinai Dept. of Psychiatry, 2008
`O. Associate Member (Elected), American College of Neuropsychopharmacology, 2009
`P. NARSAD Independent Investigator Award, 2009
`Q. Corresponding Member (Invited), European College of Neuropsychopharmacology, 2010
`R. Nominee, Ziskind-Somerfeld Award, Society of Biological Psychiatry, 2010
`S. Faculty Recognition Award, Mount Sinai School of Medicine, Dept of Education, 2010
`T. Outstanding Faculty Teaching Award, Selected by BCM Graduating Psychiatry Resident Class,
`2012
`U. “Young Leader in Mental Health”, The Menninger Clinic Our Future in Mind Program, 2012
`V. Researcher of the Year (Finalist), Psychiatry, Michael E. Debakey VA Medical Center, 2012
`W. Best Doctors, Inc. 2011-2016
`X. Member (Elected), American College of Neuropsychopharmacology 2016
`
`
`
`
`
`2. Board Eligibility/Certification
`A. Diplomate, American Board of Psychiatry and Neurology, 2002 (recertification 2012)
`Certified- Meeting MOC Requirements (2013-2015)
`
`
`
`Page 2
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`
`3
`
`II. RESEARCH INFORMATION
`
`
`A. Research Support
`1. Current:
`A. NMDA Receptor Modulation for Hyperarousal in PTSD. National Institute of Mental Health.
`Principal Investigator. 09/21/16-7/31/18. R61MH10540-01. $463,080 (direct cost, yr 1)
`B. Ketamine for Treatment-Resistant Late-Life Depression. Department of Veterans Affairs (Merit
`Grant). Principal Investigator; 9/1/2015-8/31/2020; CX001205-01A1. $702,025.00
`C. A Phase 2a Study to Evaluate the Kappa Opioid Receptor as a Target for the Treatment of Mood
`and Anxiety Spectrum Disorders by Evaluating Whether LY2456302 Engages Key Neural
`Circuitry Related to the Hedonic Response. National Institute of Mental Health. Subcontract
`Principal Investigator (Krystal, PI, Duke University); 08/29/13-12/31/17; Contract No:
`HHSN27120120000061; $477,590.00.
`D. Electroconvulsive Therapy versus Ketamine for Severe Resistant Depression. Patient-Centered
`Outcomes Research Institute (PCORI). Subcontract PI (Anand, PI, Cleveland Clinic); 9/1/16-
`8/31/2021. $2,155,825.00
`E. Switching versus Augmentation in Treatment-resistant Depression. PCORI. Subcontract PI
`(Papakostas, PI, Mass General); 9/1/16-8/31/2021. $777,280.00
`F. Developing Neuronal KCNQ Channel Modulators for Mood Disorders. National Institute of
`Mental Health. Subcontract PI (Murrough PI, Mt Sinai); 12/1/16-11/30/18. R61MH111932-01.
`$206,281.00 (direct costs, yr 1)
`G. A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to
`a Monoaminergic Antidepressant in Adults with Major Depressive Disorder. Janssen Research
`& Development; Principal Investigator; 2016-2017; CNTO136MDD2001; $105,000.00
`H. A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy,
`Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in
`Adult Subjects with Treatment-resistant Depression. Janssen Research & Development; Co-
`investigator (Shah, PI). $1,440,000.00 (maximum)
`I. The role of the reward system in suicidal ideation and behavior. American Foundation for Suicide
`Prevention, Standard Research Grant. Co-investigator (Salas, PI); 2015-2017; SRG-2-125-14.
`$90,000;
`
`
`2. Awarded (not yet begun):
`A. Glutamate receptor and kynurenine pathway functioning in the pathobiology of Gulf War Illness.
`Department of Defense Office of Congressionally Directed Medical Research Programs
`(CDMRP). Gulf War Illness Research Program New Investigator Award. Co-investigator (Lijffijt,
`PI); 2017-2020. Total Budget: $760,405.
`
`
`3. Mentor/Advisor (past):
`A. Functional MRI studies of emotion in depression and rapid antidepressant response. National
`Institute of Mental Health; Co-mentor (Murrough, PI, Mount Sinai School of Medicine); 2011-
`2016; $176,357; K23MH094707
`
`
`
`Page 3
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`
`4
`
`B. Brief potent glutamatergic modulation: applications for cocaine dependence. National Institute on
`Drug Abuse; Co-mentor (Dakwar, PI, Columbia University); 2011-2016; $186,192; K23DA031771-
`02
`4. Funded Research/Grant Support—Past:
`A. Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of Ketamine Therapy in
`Treatment-resistant Depression (TRD). National Institute of Mental Health. Subcontract
`Principal Investigator (Fava, PI, Massachusetts General Hospital); 09/12/13-02/28/17; Contract
`No.: HHSN2712011000006I; $791,887.00
`
`B. 2/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression. National Institute
`of Mental Health; Principal Investigator; 2010-2015; $750,000 (Direct Costs); R01 MH085054-
`03.
`C. 2/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression: Neurotropic factors
`and peripheral biomarkers. National Institute of Mental Health; Principal Investigator; 2012-
`2015; $68,467; R01 MH085054-03S1 [scientific supplement]
`D. Evaluation of the Efficacy of the CRF1 Antagonist GSK561679 in Women with PTSD. National
`Institute of Mental Health; Subcontract PI (Mayberg, PI, Emory University); 2012-2015;
`$332,155; U19MH069056.
`E. Optimization of IV Ketamine for Treatment Resistant Major Depression. National Institute of
`Mental Health; Principal Investigator; 2009-2014; $1,064,832; R01 MH081870.
`F. The role of habenula in major depression. Brain Behavior Research Foundation Young
`Investigator Award; Co-mentor (Ralas, PI, Baylor College of Medicine); 2013-2015; $60,000.
`G. NMDA Receptor in Psychosis: Specific Auto-antibodies. FY2016 MEDVAMC Seed Grant Award.
`Co-investigator (M. Davis, PI). 10/01/15-09/30/16; $25,000.00
`H. Ketamine vapour as a treatment for acute suicidality. MEDVAMC Seed Grant Award. Co-
`investigator (Salas, PI). 01/01/15-12/31/15; $25,000.00
`I. A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of
`intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder,
`including suicidal ideation, in subjects assessed to be at imminent risk for suicide. Janssen
`Research & Development. Site PI. 9/1/2014-6/30/2015; $15,000.00
`J. A 12-week, Randomized, Double-Blind, Controlled Evaluation followed by an Open-Label 12-
`Week Follow-up period of the impact of genesight psychotropic on response to psychotropic
`treatment in outpatients suffering from a Major Depressive Disorder (MDD) and having had-
`within the current episode- An inadequate response to at least one psychotropic medication
`included in genesight psychotropic. Assurex. Co-investigator (Shah, PI). 10/28/2014-
`10/27/2019; $134,400.00
`K. An exploratory, multicenter, single-blind, fMRI study of fixed-dose brexpiprazole (OPC-34712) as
`an adjunctive treatment in adults with major depressive disorder and irritability. Otsuka
`
`Pharmaceutical Co., Ltd. Principal Investigator. 06/01/15-05/31/16; $182,416.00
`L. Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase II Efficacy
`and Safety Study of 2 Dose Groups of AZD6765 Adjunct to Current Antidepressant Therapy in
`Patients with Major Depressive Disorder who exhibit an Inadequate Response to
`Antidepressants. AstraZeneca; Principal Investigator, 2013-2014, $200,000.
`
`
`
`Page 4
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`
`5
`
`M. Efficacy and safety of RO4995819 versus placebo as adjunctive therapy in patients with major
`depressive disorders. Roche Pharmaceuticals. Co-investigator (Shah, PI); 2012-2013,
`$129,031.82.
`N. Blood Biomarkers of Ketamine Response. NARSAD: The Brain Behavior Fund, Independent
`Investigator Award; Principal Investigator; 2009-2013; $100,000.
`O. Proton MRS Studies in Generalized Anxiety Disorder. National Institute of Mental Health;
`Principal Investigator; 2004-2009; $756,000; K23
`P. A multicenter, randomized, double-blind, active-controlled, comparative, fixed-dose, dose-response
`study of the efficacy and safety of BMS-820836 in patients with treatment-resistant major
`depression. Bristol-Myers Squibb. Co-investigator (Shah, PI); 2011-2013. $207,285.72
`Q. A Randomized, Double-Blind, Parallel-Group, Active-and Placebo-Controlled Study to Assess
`the Efficacy and Safety of JNJ-26489112 in Adult Subjects with Major Depressive Disorder.
`Johnson and Johnson; Co-investigator (Shah, PI); 2010-2011. $71,109.49.
`R. Randomized, placebo-controlled trial of an AMPAkine in major depressive disorder. National
`Institute of Mental Health; Co-Investigator (Charney, PI). 2006-2008; $455,157; U01
`S. Emory-GSK-NIMH Collaborative Mood Disorders Initiative. National Institute of Mental Health;
`Co-Investigator (Nemeroff, PI, Emory University School of Medicine). 2004-2009; Center:
`$1,221,997; Mount Sinai Site: $216,387; U19
`T. Ketamine as a Rapid Treatment for Post-Traumatic Stress Disorder. Department of
`Army/USAMRAA; Co-Investigator (Charney, PI). 2008-2012; $691,685.
`U. A 4-Week, Randomized, Double-blind, Parallel-Group Placebo-Controlled Study to Investigate
`the Safety and Efficacy of EVT 101 as Monotherapy in Patients With Treatment-Resistant Major
`Depression. Evotec Neurosciences GmbH; Co-Investigator (Shah, PI). 2010-2011. $198,872.03
`V. 1H MRS Neurometabolites as Diagnostic Markers for Chronic Fatigue Syndrome. Chronic
`Fatigue and Immune Dysfunction Syndrome (CFIDS) Association Research Grant; Co-
`Investigator; (Shungu, PI); 2009-2010; $100,000.
`W. A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study evaluating the
`efficacy and safety of orvepitant in subjects with major depressive disorder. GlaxoSmithKline
`Pharmaceuticals; Co-Principal Investigator (MSSM site); 2009-2010; $96,000.
`X. An exploratory fixed dose randomized double-blind parallel group placebo-controlled study of the
`safety and of the therapeutic effects of Ro 4917523 in patients with treatment-resistant
`depression. Hoffman La-Roche; Principal Investigator; 2008-2010; $422,877.
`Y. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy
`(ADT) among outpatients with MDD who have responded inadequately to prior ADT. MGH
`Clinical Trials Network and Institute; Principal Investigator (MSSM site) (Fava, PI, MGH); 2008-
`2009; $119,350.
`Z. Continuation Riluzole in the Prevention of Relapse Following IV Ketamine in Major Depression.
`NARSAD, Young Investigator Award; Principal Investigator; 2006-2008; $60,000.
`AA. Continuation IV Ketamine for Treatment Resistant Depression. NARSAD, Distinguished
`Investigator Award; Co-Investigator (Charney, PI). 2006-2007; $100,000.
`
`
`
`Page 5
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`
`6
`
`BB. 1H MRS Neurometabolites as Diagnostic Markers for Chronic Fatigue Syndrome. Chronic
`Fatigue and Immune Dysfunction Syndrome (CFIDS) Association Research Grant; Co-
`Investigator (Shungu, PI); 2004-2005; 2006-2007; $200,000.
`CC. A 52-week, randomized, double-blind, placebo-controlled, multi-center, parallel-group study of
`the long-term efficacy, tolerability and safety of agomelatine 25 mg and 50 mg in the prevention
`of relapse of Major Depressive Disorder (MDD) following open-label treatment of 16-24 weeks.
`Novartis Pharmaceuticals; Principal Investigator; 2007-2009; $340,524.
`DD. Investigation of a Single Dose of StaccatoTM Alprazolam for Inhalation on Doxapram-Induced
`Panic Attack in Patients with Panic Disorder. Alexza Pharmaceuticals, Inc.; Principal Investigator;
`2006-2008; $304,589.
`EE. A Multicenter, Open-Label Study to Assess the Tolerability and Efficacy of PRX-00023 in
`Patients with Generalized Anxiety Disorder. Predix Pharmaceuticals, Inc.; Principal Investigator;
`2005-2006; $100,000.
`FF. Neuroimaging studies of depressed adolescents grown up. American Foundation for Suicide
`Prevention Young Investigator Award; Principal Investigator; 2001-2004; $70,000.
`GG. A pilot investigation of riluzole in anxiety disorders with assessment of neuronal viability.
`Frontier Fund of Columbia University; Principal Investigator; 2001-2003; $20,000.
`HH. Proton magnetic resonance spectroscopy studies of adversely reared non-human primates.
`NARSAD, Young Investigator Award; Principal Investigator; 2001-2002, $60,000.
`II. Proton MRS in Variable Foraging Demand Primates: pilot work. Psychiatric Institute Research
`Support Grant; Principal Investigator; 2001-2002; $5,000.
`5. Pending:
`A. Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition. NIMH
`Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) R01. Co-
`investigator (Rebecca Price, University of Pittsburgh, PI); 2017-2022; $2,254,537
`B. Utilizing multi-method computational psychiatry to disentangle the psychobiological comorbidity
`of anxiety and depression. NIMH. Primary mentor (Patriquin, PI, BCM); 2016-2010;
`K23MH112982-01
`C. Structure of suicidal behavior and risk. NIMH. Co-investigator (Alan Swann, PI).
`R01MH109483-01A1; 2017-2022
`D. DBS for depression using directional current steering and individualized network targeting.
`NINDS. Co-investigator (Sheth/Goodman PIs). UH3 NS103549; 2017-2022
`E. Ketamine Vapour as a Treatment for Acute Suicidality. Department of Veterans Affairs. RR&D
`Small Projects in Rehabilitation Research (SPIRE); Co-investigator (Salas, PI); 2014-2016;
`$199,366.00; RX001763-01
`
`B. National Scientific Participation: (include dates and titles)
`1. Journal editorial boards, etc.
`A. Consulting Editor, Bulletin of the Menninger Clinic, 2011-2014
`B. Associate Editor, BMC Psychiatry, 2013-present
`C. Advisory Editor, Psychopharmacology, 2015-present
`D. Editorial Board, Journal of Affective Disorders, 2015-present; Chronic Stress, 2016-present
`
`
`
`Page 6
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`
`7
`
`2. Review panels, etc.
`A. Ad-Hoc Reviewer (2004-present): American Journal of Psychiatry, Biological Psychiatry,
`International Journal of Neuropsychopharmacology; JAMA Psychiatry, Journal of Clinical
`Psychiatry; Journal of Psychiatric Practice; Journal of Psychiatric Research; Medical
`Hypotheses, Molecular Psychiatry, Neuropsychopharmacology
`B. Member, NIH ZRG1 F02a Special Emphasis Panel, 2009
`C. Reviewer, Ontario Mental Health Foundation, 2009
`D. Member, NIMH Special Emphasis Panel, ZMH1-ERB-F, 2010
`E. Ad-hoc Reviewer, Women’s Health Research at Yale, Pilot Project Program, 2010
`F. Reviewer, Research Grant, Medical Research Council, UK (2011, 2013)
`G. Member, NIH Initial Review Group, Interventions Committee for Adult Disorders, 2010-2014
`H. Scientific Advisor/Grant Reviewer, American Foundation for Suicide Prevention, 2012-present
`I. External Reviewer, The Wellcome Trust, Intermediate Level Research Fellowship, 2012
`J. Chairman, DSMB, NIMH clinical trial of D1 agonist for cognition in schizotypal PD, 2013-present
`K. International Reviewer, Heath Research Awards, Health Research Board (Ireland), 2013
`L. Reviewer, ZRG1 EMNR-D 55R, NIH Special Emphasis Panel, 2014
`M. Reviewer, National Institute of General Medical Sciences SEP, ZGM1 PPBC-Y, 2015
`N. Reviewer, Dutch Brain Foundation, 2015
`O. Member, DSMB, South Texas Research Organizational Network Guiding Studies on Trauma and
`Resilience (STRONG STAR) Consortium for Treatment of PTSD, 2015-present
`P. Reviewer, NIMH Fellowships and Dissertation Grants, ZMH1 ERB-B, 2016 (March, Dec)
`Q. Reviewer, ZAT1 HS-25 Clinical Research on Mind-Body Interventions Study Section, National
`Center for Complementary and Integrative Health (NCCIH), 2016
`R. Reviewer, XMH1 ERB-D NIMH Special Emphasis Panel, 2017
`S. Reviewer, Early Stage Testing of Pharmacologic or Device-based interventions for the treatment
`of mental disorders (2017/10 ZMH1 ERB-D (08), 06/07/2017
`3. Professional Societies
`A. Organizational Memberships
`1. American Psychiatric Association/Texas Society of Psychiatric Physicians
`a. Council on Research Task Force (subgroup on treatment recommendations for
`ketamine), 2016-present
`2. American Medical Association
`3. Anxiety and Depression Association of America
`a. Publications Committee, 2003-2005
`b. Reviewer, Scientific Abstracts/Symposia, 2004, 2007
`c. Program Committee, 2014-present
`d. Chair, Research Subcommittee, 2015-present
`e. Chair, Program Committee, 2017-2018
`4. International Society of Magnetic Resonance in Medicine
`5. Society of Biological Psychiatry
`a. Scientific Program Committee, 2010-2013; 2016-2019
`6. Society for Neuroscience
`
`
`
`
`
`
`
`Page 7
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`
`8
`
`
`
`7. American College of Neuropsychopharmacology
`a. Associate Member, 2009-2015; Member, 2016-
`b. Mentor, 2011-2015
`8. European College of Neuropsychopharmacology (Corresponding Member)
`9. American Society of Clinical Psychopharmacology
`a. Awards Committee, 2015-present
`10. National Network of Depression Centers
`a. Executive Committee, 2014-present
`4. Invited lectures, presentations, research seminars: National, International
`A. See SECTION III, D. Lectures—National, International
`C. Publications
`1. Full papers:
`A. Published in peer review journals
`1. Mathew SJ, Yudofsky SC, McCullough LB, Teasdale TA, Jankovic J: Attitudes towards
`neurosurgical procedures for Parkinson’s disease and obsessive-compulsive disorder: results
`of a national survey of neurologists and psychiatrists. J Neuropsychiatry Clin Neuroscience
`11 (2): 259-267, 1999.
`2. Mathew SJ, Fallon BA, Simpson HB: Treatment strategies for obsessive-compulsive disorder.
`Psychiatric Annals 30(11): 699-708, 2000.
`3. Coplan JD, Mathew SJ, Smith ELP, Trost RC, Scharf BA, Martinez J, Gorman JM, Monn JA,
`Schoepp DD, Rosenblum LA: Effects of LY354740, a novel glutamatergic metabotropic
`agonist, on nonhuman primate hypothalamic-pituitary-adrenal axis and noradrenergic function.
`CNS Spectrums 6 (7): 607-617, 2001.
`4. Fallon BA, Mathew SJ: Biological therapies for obsessive compulsive disorder. Journal of
`Psychiatric Practice 6: 113-128, 2001.
`5. Mathew SJ, Coplan JD, Gorman JM: Neurobiological mechanisms of social anxiety disorder.
`Am J Psychiatry 158 (10): 1558-1567, 2001.
`6. Mathew SJ, Coplan JD, Perko K, Goetz RR, de la Nuez M, Hollander E, Liebowitz MR, Fallon
`BA: Neuroendocrine predictors of response to intravenous clomipramine for refractory
`obsessive-compulsive disorder. Depress Anxiety 14 (4):199-208, 2001.
`7. Mathew SJ, Coplan JD, Gorman JM: Management of treatment-refractory panic disorder.
`Psychopharmacology Bulletin 35 (2): 97-110, 2001.
`8. Mathew SJ, Coplan JD, Smith ELP, Schoepp DD, Rosenblum LA, Gorman JM: Glutamate-
`hypothalamic-pituitary-adrenal axis interactions: implications for mood and anxiety disorders.
`CNS Spectrums 6 (7): 555-564, 2001.
`9. Mathew SJ, Coplan JD, Smith ELP, Scharf BA, Owens MJ, Nemeroff CB, Mann JJ, Gorman
`JM, Rosenblum LA: Cerebrospinal fluid concentrations of biogenic amines and corticotropin-
`releasing factor in adolescent non-human primates as a function of the timing of adverse early
`rearing. Stress 5(3): 185-193, 2002.
`10. Gorman JM, Mathew SJ, Coplan JD: Neurobiology of early life stress. Semin Clin
`Neuropsychiatry Apr; 7 (2): 96-103, 2002.
`
`
`
`Page 8
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`
`9
`
`11. Kent JM, Mathew SJ, Gorman JM: Molecular targets in the treatment of anxiety. Biol
`Psychiatry 52 (10): 1008-1030, 2002.
`12. Mathew SJ, Coplan JD, Goetz RR, Feder A, Greenwald S, Dahl RE, Ryan ND, Mann JJ,
`Weissman MM: Differentiating depressed adolescent twenty-four hour cortisol secretion in
`light of their adult clinical outcome. Neuropsychopharmacology 28 (7): 1336-1343, 2003.
`13. Mathew SJ, Shungu DC, Mao X, Smith ELP, Perera GM, Kegeles LS, Perera T, Lisanby SH,
`Rosenblum LA, Gorman JM, Coplan JD: A magnetic resonance spectroscopic imaging study
`of adult nonhuman primates exposed to early-life stressors. Biol Psychiatry 54 (7): 727-735,
`2003.
`14. Mathew SJ, Mao X, Coplan JD, Smith ELP, Sackeim HA, Gorman JM, Shungu DC:
`Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic
`resonance spectroscopic imaging study. Am J Psychiatry 161 (6): 1119-1121, 2004.
`15. Feder A, Goetz RR, Coplan JD, Mathew SJ, Pine DS, Greenwald S, Dahl RE, Ryan ND,
`Weissman MM: Twenty-four hour cortisol secretion patterns in prepubertal children with
`anxiety or depressive disorders. Biol Psychiatry 56: 198-204, 2004.
`16. Mathew SJ, Amiel JA, Sackeim HA: Electroconvulsive therapy for treatment resistant
`depression. Primary Psychiatry 12: 52-56, 2005.
`17. Mathew SJ: Exploring Glutamate Function in Mood and Anxiety Disorders: Rationale and
`Future Directions. CNS Spectrums 10: 806-807, [invited guest editorial] 2005.
`18. Mathew SJ, Keegan K, Smith L: Experimental therapeutics for mood disorders: focus on
`glutamate modulators. Brazilian Journal of Psychiatry 27 (3): 243-8, 2005.
`19. Mathew SJ, Amiel JA, Coplan JD, Fitterling H, Sackeim HA, Gorman JM: Open-label trial of
`riluzole in generalized anxiety disorder. Am J Psychiatry 162 (12): 2379-2381, 2005.
`20. Coplan JD, Altemus MA, Mathew SJ, Smith ELP, Scharf B, Coplan PM, Kral JS, Gorman JM,
`Owens MJ, Nemeroff CB, Rosenblum LA: Synchronized maternal-infant elevations of primate
`CSF CRF concentrations in response to variable foraging demand. CNS Spectrums 10: 530-
`536, 2005.
`21. Mathew SJ, Ho S: Etiology and neurobiology of social anxiety disorder. J Clin Psychiatry 67
`Suppl 12: 9-13, 2006.
`22. Garakani A, Mathew SJ, Charney DS: Neurobiology of anxiety disorders and implications for
`treatment. Mt. Sinai J Med 73 (7): 941-9, 2006.
`23. Mathew SJ, Burd S: The bidirectional relationship between depression and diabetes.
`Depress: Mind Body 2 (4): 131-4, 2006.
`24. Coplan JD, Mathew SJ, Mao X, Smith EL, Hof PR, Coplan PM, Rosenblum LA, Gorman JM,
`Shungu DC. Decreased choline and creatine concentrations in centrum semiovale in patients
`with generalized anxiety disorder: relationship to IQ and early trauma. Psychiatry Research:
`Neuroimaging 147 (1): 27-39, 2006.
`25. Coplan JD, Smith ELP, Altemus M, Mathew SJ, Perera T, Kral JG, Gorman JM, Owens MJ,
`Nemeroff CB, Rosenblum LA: Maternal-infant response to variable foraging demand in
`nonhuman primates: effects of timing of stressor on cerebrospinal fluid corticotropin-releasing
`factor and circulating glucocorticoid concentrations. Ann NY Acad Sci 1071: 525-533, 2006.
`
`
`
`Page 9
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`
`10
`
`26. Amiel JA, Mathew SJ: Glutamate and Anxiety Disorders. Curr Psychiatry Rep 9 (4): 278-83,
`2007.
`27. Mathew SJ, Price RB, Mao X, Smith ELP, Coplan JD, Charney DS, Shungu DC:
`Hippocampal N-Acetylaspartate Concentration and Response to Riluzole in Generalized
`Anxiety Disorder. Biol Psychiatry 63 (9): 891-898, 2008.
`28. Mathew SJ, Price RB, Charney DS: Recent advances in the neurobiology of anxiety
`disorders: implications for novel therapeutics, Am J Med Genetics Part C: Seminars in Med
`Genetics 148C: 89-98, 2008.
`29. Hoffman EJ, Mathew SJ: Anxiety disorders: a comprehensive review of pharmacotherapies.
`Mt Sinai J Med 75 (3): 248-262, 2008.
`30. Dumitriu D, Collins KA, Alterman R, Mathew SJ: Neurostimulatory therapeutics in the
`management of treatment-resistant depression—special focus on deep brain stimulation. Mt
`Sinai J Med 73 (3): 263-275, 2008.
`31. aan het Rot M, Charney DS, Mathew SJ: Intravenous Ketamine for Treatment-Resistant
`Depression. Primary Psychiatry 15 (4): 39-47, 2008.
`32. Mathew SJ, Manji HK, Charney DS: Novel drugs and therapeutic targets for severe mood
`disorders. Neuropsychopharmacology 33 (9): 2080-2092, 2008.
`33. Rickels K, Mathew SJ, Banov MD, Zimbroff DL, Oshana S, Parsons EC, Kauffman M, Iyer
`GR, Donahue SR, Reinhard JF: Effects of PRX-00023, a novel, selective serotonin 1A
`receptor agonist on measures of anxiety and depression in generalized anxiety disorder:
`results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol 28 (2), 235-9,
`2008.
`34. Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S: Preliminary evidence of short-
`term efficacy of a novel, non-azapirone selective 1A agonist in generalized anxiety disorder.
`Clin Therapeutics 30 (9): 1658-1666, 2008.
`35. Mathew SJ: Treatment-resistant depression: recent developments and future directions.
`Depress Anxiety 25 (12): 989-992, 2008.
`36. Mathew SJ, Mao X, Keegan KA, Levine SM, Smith ELP, Otcheretko V, Coplan JD, Shungu
`DC: Elevated Ventricular Lactate in Chronic Fatigue Syndrome: A Proton Magnetic
`Resonance Spectroscopic Imaging Study. NMR Biomed 22 (3): 251-258, 2009.
`37. Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough J, Charney DS,
`Mathew SJ: Amino acid neurotransmitter concentrations in anterior cingulate and occipital
`cortex in symptomatic patients with major depression: relationship to treatment resistance.
`Biol Psychiatry 65 (9): 792-800, 2009.
`38. Price RB, Nock MT, Charney DS, Mathew SJ: Effects of intravenous ketamine on explicit and
`implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66 (5): 522-
`526, 2009.
`39. aan het Rot M, Mathew SJ, Charney DS: Neurobiological mechanisms in major depressive
`disorder. CMAJ 180 (3): 305-313, 2009.
`40. Mathew SJ, Charney DS: Publication bias and the efficacy of antidepressants. Am J
`Psychiatry 166 (2): 140-145, 2009.
`
`
`
`Page 10
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`
`11
`
`41. Alterman RL, Dumitriu D, Mathew S: Deep brain stimulation for major depressive disorder.
`Clinical Neuropsychiatry, 6 (6): 259-265, 2009.
`42. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ:
`Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
`Biol Psychiatry 67 (2): 139-145, 2010.
`43. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS: Riluzole for
`relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot
`randomized, placebo-controlled continuation trial. Int J Neuropsychopharm 13 (1): 71-82,
`2010.
`44. Abdallah CG, Tang CY, Mathew SJ, Martinez J, Hof PR, Perera TD, Shungu DC, Gorman
`JM, Coplan JD: Diffusion tensor imaging in studying white matter complexity: a gap junction
`hypothesis. Neurosci Lett. 475 (3): 161-164, 2010.
`45. Krystal JH, Mathew SJ, D’Souza DC, Garakani A, Gunduz-Bruce H, Charney DS: Potential
`psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS
`Drugs 24 (8): 669-693, 2010.
`46. Coplan JD, Abdallah CG, Tang CY, Mathew SJ, Martinez J, Hof PR, Smith EL, Dwork AJ,
`Perera TD, Pantol G, Carpenter D, Rosenblum LA, Shungu DC, Gelernter J, Kaffman A,
`Jackowski A, Kaufman J, Gorman JM: The role of early life stress in development of the
`anterior limb of the internal capsule in nonhuman primates. Neurosci Lett. 480(2):93-6, 2010.
`47. Murrough JW, Mao X, Collins K, Kelly C, Andrade G, Nestadt P, Levine S, Mathew SJ*,
`Shungu DC: Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS
`imaging at 3.0 T. II: Comparison with major depressive disorder. NMR Biomed 23 (6): 643–
`650, 2010. *co-senior author
`48. Mathew S, Price R, Shungu D, Mao X, Smith E, Amiel J, Coplan J. A pilot study of the effects
`of chronic paroxetine administration on hippocampal N-acetylaspartate in generalized anxiety
`disorder. J Psychopharmacol 24(8): 1175-1181, 2010. PMCID: PMC19204062
`49. Coplan JD, Mathew SJ, Abdallah CG, Mao X, Kral JG, Smith ELP, Rosenblum LA, Perera
`TD, Dwork AJ, Gorman JM, Hof PR, Shungu DC: Early-life stress and neurometabolites of the
`hippocampus. Brain Research 1358: 191-199, 2010.
`50. Jackowski A, Perera TD, Abdallah CG, Garrido G, Tang CY, Martinez J, Mathew SJ, Gorman
`JM, Rosenblum LA, Smith ELP, Dwork AJ, Shungu DC, Kaffman A, Gelernter J, Coplan JD,
`Kaufman J: Early-life stress, corpus callosum development, hippocampal volumetrics, and
`anxious behavior in male nonhuman primates. Psychiatry Research 192 (1); 37-44, 2011.
`51. Mathew SJ, Vythilingam M, Feder A, Zarate CA Jr, Luckenbaugh D, Parides M, Trist D, Bani
`M, Bettica P, Ratti E, Charney DS: A selective neurokinin-1 receptor antagonist in chronic
`PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur
`Neuropsychopharmacol 21 (3): 221-229, 2011. PMID: 21194898
`52. Feder A, Skipper J, Blair JR, Buchholtz K, Mathew SJ, Schwarz M, Doucette J, Alonso A,
`Collins KA, Neumeister A, Charney DS: Tryptophan depletion and emotional processing in
`healthy volunteers at high risk for depression. Biol Psychiatry, 69 (8): 804-807, 2011.
`53. Coplan JD, Abdallah CG, Mathew SJ, Shungu DC, Mao X, Smith ELP, Kaufman D, Gorman
`JM, Owens MJ, Nemeroff CB, Banerji MA, Rosenblum LA, Kral J: Metabolic syndrome and
`
`
`
`Page 11
`
`

`

`01 JULY 2017
`
`
`
`
` S.J. Mathew, M.D.
`